Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain
Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )
22 Dec 2022

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL

Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )
21 Dec 2022

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma

Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA
Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma ( Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA )
20 Dec 2022

What is required to advance data ethics, data sharing, and Open Science across LMICs

Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India
What is required to advance data ethics, data sharing, and Open Science across LMICs ( Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India )
20 Dec 2022

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
19 Dec 2022

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer

Dr Ruth O'Regan - University of Rochester, Rochester, USA
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )
19 Dec 2022

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease

Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA
Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease ( Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA )
15 Dec 2022

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC

Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA
Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC ( Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA )
14 Dec 2022

Opinion: Premature regulatory approval by the FDA

Dr Bishal Gyawali - Queen's University, Kingston, Canada
Opinion: Premature regulatory approval by the FDA ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
13 Dec 2022

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma

Dr Emma Searle - University of Manchester, Manchester, UK
Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma ( Dr Emma Searle - University of Manchester, Manchester, UK )
12 Dec 2022

The future of precision oncology

Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany
The future of precision oncology ( Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany )
7 Dec 2022